Updates from 2nd Generation URBAN ARCH HIV/Alcohol P01s

The ARCHER team is excited to announce the accomplishment of a few major milestones for its Physical Activity Trial and its Pain Trial.  In December 2022, the ARCHER team received approval for both trials from the Boston University Medical Campus Institutional Review Board.

With IRB-approval in hand to begin human subjects research activities, we launched our online recruitment campaign with our collaborators at BuildClinical, a vendor with expertise in creating and targeting research advertisements to populations based on study-specific criteria. Our recruitment campaign rolled out online advertisements to 16 metropolitan areas across the Unites States. During the first week of our recruitment campaign, more than 180 interested and potentially eligible participants submitted an online pre-screening form. The ARCHER team is currently reviewing completed pre-screening forms, and reaching out to potentially eligible participants for further eligibility screening and trial enrollment.  We currently have 11 participants enrolled overall: 5 in the Physical Activity Trial and 6 in the Pain Trial. These participants have consented, completed the baseline interview, and are actively participating in the 15 days of ecological momentary assessment data collection and 15 days of Fitbit wear (for Physical Activity Trial participants only). Through this process, the team has been monitoring data closely with our collaborators at the Boston University Biostatistics and Epidemiology Data Analytics Center (BEDAC) in REDCap, MetricWire (a specialized mobile application for research data collection), and Fitabase (a platform used to collect Fitbit data).

We invite any interested investigators who wish to use existing Boston ARCH data for secondary analysis to contact Dr. Stein or Kara Magane for additional information.

META HIV CVD and ARCHER held their first joint DSMB meeting in Fall 2022. META HIV CVD RCT (project 1) will begin enrollment at Vanderbilt University Medical Center in April 2023. META HIV CVD (project 2) has successfully completed initial analyses that will be presented at the Research Society on Alcoholism meeting in June 2023. In conjunction with ARCHER, URBAN ARCH, HARP, SHARC, and other researchers, META HIV will host the second annual alcohol and HIV satellite meeting at the RSA annual meeting in Bellevue, WA on June 24, 2023. Please click here to view an informational flyer for the satellite meeting. You can register for the meeting here.